Miyamoto S - Search Results

1

Antitumour Effects of Intravenous Administration of BK-UM, a Novel Inhibitor of HB-EGF, in Ovarian Cancer Therapy.

Fukagawa S, Yotsumoto F, Odawara T, Manabe S, Ishikawa T, Yasunaga S, Miyamoto S. Fukagawa S, et al. Among authors: miyamoto s. Anticancer Res. 2017 Jul;37(7):3891-3896. doi: 10.21873/anticanres.11770. Anticancer Res. 2017. PMID: 28668891

2

New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.

Miyamoto S, Yagi H, Yotsumoto F, Horiuchi S, Yoshizato T, Kawarabayashi T, Kuroki M, Mekada E. Miyamoto S, et al. Anticancer Res. 2007 Nov-Dec;27(6A):3713-21. Anticancer Res. 2007. PMID: 17970033 Free article. Review.

3

Emerging strategies for ErbB ligand-based targeted therapy for cancer.

Tsujioka H, Yotsumoto F, Shirota K, Horiuchi S, Yoshizato T, Kuroki M, Miyamoto S. Tsujioka H, et al. Among authors: miyamoto s. Anticancer Res. 2010 Aug;30(8):3107-12. Anticancer Res. 2010. PMID: 20871027 Review.

4

HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer.

Sanui A, Yotsumoto F, Tsujioka H, Fukami T, Horiuchi S, Shirota K, Yoshizato T, Kawarabayashi T, Kuroki M, Miyamoto S. Sanui A, et al. Among authors: miyamoto s. Anticancer Res. 2010 Aug;30(8):3143-9. Anticancer Res. 2010. PMID: 20871033

5

A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.

Tsujioka H, Fukami T, Yotsumoto F, Ueda T, Hikita S, Takahashi Y, Kondo H, Kuroki M, Miyamoto S. Tsujioka H, et al. Among authors: miyamoto s. Anticancer Res. 2011 Jul;31(7):2461-5. Anticancer Res. 2011. PMID: 21873160

6

Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.

Kunami N, Yotsumoto F, Ishitsuka K, Fukami T, Odawara T, Manabe S, Ishikawa T, Tamura K, Kuroki M, Miyamoto S. Kunami N, et al. Among authors: miyamoto s. Anticancer Res. 2011 Jul;31(7):2483-8. Anticancer Res. 2011. PMID: 21873163

7

Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA.

Hikita S, Yotsumoto F, Fukami T, Horiuchi S, Sanui A, Miyata K, Nam SO, Tsujioka H, Ueda T, Shirota K, Yoshizato T, Maeda K, Ishikawa T, Okuno Y, Kuroki M, Mekada E, Miyamoto S. Hikita S, et al. Among authors: miyamoto s. Anticancer Res. 2011 Jul;31(7):2553-9. Anticancer Res. 2011. PMID: 21873174

8

Regulatory mechanisms of the HB-EGF autocrine loop in inflammation, homeostasis, development and cancer.

Miyata K, Yotsumoto F, Nam SO, Kuroki M, Miyamoto S. Miyata K, et al. Among authors: miyamoto s. Anticancer Res. 2012 Jun;32(6):2347-52. Anticancer Res. 2012. PMID: 22641673 Review.

9

Possible therapeutic targets among the molecules involved in the Warburg effect in tumor cells.

Nam SO, Yotsumoto F, Miyata K, Shirasu N, Miyamoto S, Kuroki M. Nam SO, et al. Among authors: miyamoto s. Anticancer Res. 2013 Jul;33(7):2855-60. Anticancer Res. 2013. PMID: 23780970 Review.

10

Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.

Miyata K, Yotsumoto F, Nam SO, Odawara T, Manabe S, Ishikawa T, Itamochi H, Kigawa J, Takada S, Asahara H, Kuroki M, Miyamoto S. Miyata K, et al. Among authors: miyamoto s. Cancer Med. 2014 Oct;3(5):1159-69. doi: 10.1002/cam4.301. Epub 2014 Jul 24. Cancer Med. 2014. PMID: 25060396 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,381 results

Search Page

Filters